PMLiVE |
CHMP backs GSK's asthma antibody and Novartis' heart failure drug
PMLiVE GlaxoSmithKline's mepolizumab for severe asthma and Novartis new' heart failure therapy Entresto have been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The panel issued positive opinions for the two drugs … |
View full post on asthma – Google News